Correction to today's FierceBiotech

FierceBiotech's subject line in today's e-mail for the report incorrectly identified Innate's partner in a new deal. The pact was inked with Bristol-Myers Squibb, as we report in the story, not Sanofi. We regret the error. Read the story

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.